An assessment of currently available i.v. Push medication delivery systems

John Fanikos, Maureen Burger, Todd Canada, Patricia Ebright, Joshua Fleming, Kathleen A. Harder, Julius Cuong Pham, Melinda D. Sawyer, James G. Stevenson

Research output: Contribution to journalReview article

Abstract

A small panel of experts reviewed the current evidence and guidelines regarding the administration of i.v. push medications and the adherence of HCPs and health systems to those recommendations. The panel noted that significant variation from best-practice guidelines exists in current practice. Panel members believed that barriers to the use of more ideal i.v. push drug delivery systems should be addressed by healthcare organizations, and HCPs and healthcare lead-ers should become more familiar with the risks and benefits of such systems and strive to move practice toward optimal and safer administration practices. The opinions and recommendations of the expert panel are limited by the small number of panel members, and similar assessments by a larger group of stakeholders should be conducted to validate the views of the panel. Finally, panel members recognized that, as newer devices evolve, there is a need to reevaluate the systems periodically to ensure that appropriate modifications are made to the characteristics for an ideal RTA administration system.

Original languageEnglish (US)
Pages (from-to)e230-e235
JournalAmerican Journal of Health-System Pharmacy
Volume74
Issue number9
DOIs
StatePublished - May 1 2017

Fingerprint

Medication Systems
Practice Guidelines
Delivery of Health Care
Medication Adherence
Expert Testimony
Drug Delivery Systems
Organizations
Guidelines
Equipment and Supplies
Health

Keywords

  • Drug devices
  • Medication systems
  • Patient safety
  • Product evaluation
  • Product labeling
  • Ready to administer

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Health Policy

Cite this

Fanikos, J., Burger, M., Canada, T., Ebright, P., Fleming, J., Harder, K. A., ... Stevenson, J. G. (2017). An assessment of currently available i.v. Push medication delivery systems. American Journal of Health-System Pharmacy, 74(9), e230-e235. https://doi.org/10.2146/ajhp150830

An assessment of currently available i.v. Push medication delivery systems. / Fanikos, John; Burger, Maureen; Canada, Todd; Ebright, Patricia; Fleming, Joshua; Harder, Kathleen A.; Pham, Julius Cuong; Sawyer, Melinda D.; Stevenson, James G.

In: American Journal of Health-System Pharmacy, Vol. 74, No. 9, 01.05.2017, p. e230-e235.

Research output: Contribution to journalReview article

Fanikos, J, Burger, M, Canada, T, Ebright, P, Fleming, J, Harder, KA, Pham, JC, Sawyer, MD & Stevenson, JG 2017, 'An assessment of currently available i.v. Push medication delivery systems', American Journal of Health-System Pharmacy, vol. 74, no. 9, pp. e230-e235. https://doi.org/10.2146/ajhp150830
Fanikos J, Burger M, Canada T, Ebright P, Fleming J, Harder KA et al. An assessment of currently available i.v. Push medication delivery systems. American Journal of Health-System Pharmacy. 2017 May 1;74(9):e230-e235. https://doi.org/10.2146/ajhp150830
Fanikos, John ; Burger, Maureen ; Canada, Todd ; Ebright, Patricia ; Fleming, Joshua ; Harder, Kathleen A. ; Pham, Julius Cuong ; Sawyer, Melinda D. ; Stevenson, James G. / An assessment of currently available i.v. Push medication delivery systems. In: American Journal of Health-System Pharmacy. 2017 ; Vol. 74, No. 9. pp. e230-e235.
@article{3a8d903493fa4059bade52ebe558ae29,
title = "An assessment of currently available i.v. Push medication delivery systems",
abstract = "A small panel of experts reviewed the current evidence and guidelines regarding the administration of i.v. push medications and the adherence of HCPs and health systems to those recommendations. The panel noted that significant variation from best-practice guidelines exists in current practice. Panel members believed that barriers to the use of more ideal i.v. push drug delivery systems should be addressed by healthcare organizations, and HCPs and healthcare lead-ers should become more familiar with the risks and benefits of such systems and strive to move practice toward optimal and safer administration practices. The opinions and recommendations of the expert panel are limited by the small number of panel members, and similar assessments by a larger group of stakeholders should be conducted to validate the views of the panel. Finally, panel members recognized that, as newer devices evolve, there is a need to reevaluate the systems periodically to ensure that appropriate modifications are made to the characteristics for an ideal RTA administration system.",
keywords = "Drug devices, Medication systems, Patient safety, Product evaluation, Product labeling, Ready to administer",
author = "John Fanikos and Maureen Burger and Todd Canada and Patricia Ebright and Joshua Fleming and Harder, {Kathleen A.} and Pham, {Julius Cuong} and Sawyer, {Melinda D.} and Stevenson, {James G.}",
year = "2017",
month = "5",
day = "1",
doi = "10.2146/ajhp150830",
language = "English (US)",
volume = "74",
pages = "e230--e235",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "9",

}

TY - JOUR

T1 - An assessment of currently available i.v. Push medication delivery systems

AU - Fanikos, John

AU - Burger, Maureen

AU - Canada, Todd

AU - Ebright, Patricia

AU - Fleming, Joshua

AU - Harder, Kathleen A.

AU - Pham, Julius Cuong

AU - Sawyer, Melinda D.

AU - Stevenson, James G.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - A small panel of experts reviewed the current evidence and guidelines regarding the administration of i.v. push medications and the adherence of HCPs and health systems to those recommendations. The panel noted that significant variation from best-practice guidelines exists in current practice. Panel members believed that barriers to the use of more ideal i.v. push drug delivery systems should be addressed by healthcare organizations, and HCPs and healthcare lead-ers should become more familiar with the risks and benefits of such systems and strive to move practice toward optimal and safer administration practices. The opinions and recommendations of the expert panel are limited by the small number of panel members, and similar assessments by a larger group of stakeholders should be conducted to validate the views of the panel. Finally, panel members recognized that, as newer devices evolve, there is a need to reevaluate the systems periodically to ensure that appropriate modifications are made to the characteristics for an ideal RTA administration system.

AB - A small panel of experts reviewed the current evidence and guidelines regarding the administration of i.v. push medications and the adherence of HCPs and health systems to those recommendations. The panel noted that significant variation from best-practice guidelines exists in current practice. Panel members believed that barriers to the use of more ideal i.v. push drug delivery systems should be addressed by healthcare organizations, and HCPs and healthcare lead-ers should become more familiar with the risks and benefits of such systems and strive to move practice toward optimal and safer administration practices. The opinions and recommendations of the expert panel are limited by the small number of panel members, and similar assessments by a larger group of stakeholders should be conducted to validate the views of the panel. Finally, panel members recognized that, as newer devices evolve, there is a need to reevaluate the systems periodically to ensure that appropriate modifications are made to the characteristics for an ideal RTA administration system.

KW - Drug devices

KW - Medication systems

KW - Patient safety

KW - Product evaluation

KW - Product labeling

KW - Ready to administer

UR - http://www.scopus.com/inward/record.url?scp=85018312316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018312316&partnerID=8YFLogxK

U2 - 10.2146/ajhp150830

DO - 10.2146/ajhp150830

M3 - Review article

C2 - 28438828

AN - SCOPUS:85018312316

VL - 74

SP - e230-e235

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 9

ER -